UBS analyst Manav Gupta raised the firm’s price target on Calumet (CLMT) to $13.25 from $12 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLMT:
- Calumet Specialty Products’ Strong Quarter Amidst Challenges
- Calumet Specialty Products: Strategic Positioning and Operational Improvements Drive Buy Rating
- Calumet Specialty Products: Hold Rating Amid Strategic Positioning and Future Debt Challenges
- Calumet Specialty Products Reports Q2 2025 Results
- Calumet reports Q2 EPS ($1.70) vs. (48c) last year